AstraZeneca (LON:AZN) Stock Rating Reaffirmed by Liberum Capital
Liberum Capital restated their hold rating on shares of AstraZeneca (LON:AZN) in a report published on Tuesday morning, ThisIsMoney.Co.Uk reports.
A number of other brokerages have also recently commented on AZN. Goldman Sachs Group raised their price target on shares of AstraZeneca from GBX 5,000 ($65.33) to GBX 5,500 ($71.87) and gave the stock a sell rating in a research note on Monday, August 5th. Shore Capital restated a buy rating on shares of AstraZeneca in a research note on Friday, August 9th. Deutsche Bank restated a buy rating and set a GBX 6,900 ($90.16) price target on shares of AstraZeneca in a research note on Friday, July 26th. Morgan Stanley raised their price target on shares of AstraZeneca from GBX 6,400 ($83.63) to GBX 6,500 ($84.93) and gave the stock an equal weight rating in a research note on Tuesday, May 7th. Finally, Credit Suisse Group set a GBX 7,300 ($95.39) price target on shares of AstraZeneca and gave the stock a buy rating in a research note on Friday, July 26th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of GBX 6,688.24 ($87.39).
Shares of AZN opened at GBX 7,373 ($96.34) on Tuesday. The stock has a market cap of $96.08 billion and a price-to-earnings ratio of 43.07. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. AstraZeneca has a 12 month low of GBX 5,312 ($69.41) and a 12 month high of GBX 7,475.15 ($97.68). The company has a 50-day moving average price of GBX 6,870.36 and a two-hundred day moving average price of GBX 6,274.74.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: The risks of owning bonds
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.